{"id":"sodium valproate","brandName":"Epilim","genericName":"sodium valproate","companyId":"sanofi","companyName":"Sanofi","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2"},"administration":{},"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Somnolence","drugRate":"10.7%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"7.1%","severity":"common","organSystem":""},{"effect":"Paresthesia","drugRate":"7.1%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"7.1%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"6.3%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"4.3%","severity":"common","organSystem":""},{"effect":"Injection site pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Taste perversion","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea/vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Elevated amylase","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute pancreatitis","Arginase deficiency","Arginosuccinate Lyase Deficiency","Chronic pancreatitis","Citrullinemia","Congenital hyperammonemia, type I","Depressive disorder","Disease of blood AND/OR blood-forming organ","Disease of liver","Hyperammonemia","Hypoalbuminemia","Hypothermia","Kidney disease","Organic mental disorder","Ornithine Carbamyltransferase Deficiency","Poisoning by sodium valproate","Porphyria","Pregnancy, function","Suicidal thoughts","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Hyperammonemia with encephalopathy","drugRate":"","severity":"serious"},{"effect":"Hallucinations","drugRate":"","severity":"serious"},{"effect":"Pneumonia","drugRate":"","severity":"serious"},{"effect":"Abnormal gait","drugRate":"","severity":"serious"},{"effect":"Injection site reaction","drugRate":"","severity":"serious"}]},"trials":["NCT03885154","NCT00995332","NCT01326663","NCT01295593","NCT00073164","NCT00347152","NCT00404248","NCT05920512","NCT00570219","NCT06729541","NCT01960075","NCT01552434","NCT06393309","NCT02213887","NCT02473250","NCT05181007","NCT00563992","NCT00358319","NCT04486092","NCT01170377","NCT01170325","NCT00177567","NCT00647712","NCT01333631","NCT00524667","NCT02078596","NCT01184391","NCT02124174","NCT01132183","NCT00175903","NCT00309686","NCT00004817","NCT00075010","NCT00356018","NCT00195780","NCT00579280","NCT00223496","NCT07166393","NCT02446652","NCT00308360","NCT02872428","NCT01861990","NCT00414310","NCT05263674","NCT06714357","NCT00879437","NCT03357757","NCT02896270","NCT02300051","NCT00374075"],"indications":{"approved":[{"name":"Absence seizure","diseaseId":"absence-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bipolar affective disorder, current episode manic","diseaseId":"bipolar-affective-disorder-current-episode-manic","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epilepsy","diseaseId":"epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Epilepsy characterized by intractable complex partial seizures","diseaseId":"epilepsy-characterized-by-intractable-complex-partial-seizures","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Migraine Prevention","diseaseId":"migraine-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT03885154","phase":"Phase 2","title":"Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine: An Open-Label Randomized Trial.","status":"TERMINATED","sponsor":"Kimberly S Jones","isPivotal":false,"enrollment":24,"indication":"Migraine in Children","completionDate":"2019-03-19"},{"nctId":"NCT00995332","phase":"Phase 1","title":"Treatment of Acute Myelogenous Leukemia With the Histone Deacetylase Inhibitor Valproic Cid in Combination With All-trans Retinoic Acid (ATRA) and Low Dose Cytarabine","status":"COMPLETED","sponsor":"University of Bergen","isPivotal":false,"enrollment":36,"indication":"Acute Myelogenous Leukemia","completionDate":"2013-06"},{"nctId":"NCT01326663","phase":"NA","title":"A Double Blind Trial Of Divalproex Sodium For Affective Lability And Alcohol Use Following Traumatic Brain Injury","status":"UNKNOWN","sponsor":"Paul Saenger","isPivotal":false,"enrollment":50,"indication":"Veterans, TBI","completionDate":"2013-12"},{"nctId":"NCT01295593","phase":"Phase 1","title":"Phase I-II Study of Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia (CLL) Patients","status":"UNKNOWN","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","isPivotal":false,"enrollment":33,"indication":"Chronic Lymphocytic Leukemia","completionDate":"2013-04"},{"nctId":"NCT00073164","phase":"Phase 2","title":"A Study of the Safety and Efficacy of Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Abbott","isPivotal":false,"enrollment":400,"indication":"Schizophrenia","completionDate":""},{"nctId":"NCT00347152","phase":"NA","title":"Overnight Versus Progressive Conversion of Multiple Daily Dose Enteric-Coated Divalproex to Once-Daily Divalproex Extended Release: Which Strategy is Better Tolerated by Patients With Intellectual Dis","status":"COMPLETED","sponsor":"University of Kansas","isPivotal":false,"enrollment":18,"indication":"Epilepsy","completionDate":"2007-12"},{"nctId":"NCT00404248","phase":"Phase 1","title":"Phase I/II Study of Intravenous Infusion of Tetra-o-Methyl Nordihydroguaiaretic Acid (EM-1421) in Subjects With Recurrent High Grade Glioma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":35,"indication":"Brain and Central Nervous System Tumors","completionDate":"2012-02"},{"nctId":"NCT05920512","phase":"Phase 1","title":"PLA General Hospital","status":"UNKNOWN","sponsor":"Xue-chun Lu","isPivotal":false,"enrollment":10,"indication":"Hemophilia","completionDate":"2025-04-01"},{"nctId":"NCT00570219","phase":"NA","title":"The Effect of Valproate Treatment on Withdrawal Severity in Benzodiazepine Dependent Opioid Maintenance Treatment Patients","status":"COMPLETED","sponsor":"University of Helsinki","isPivotal":false,"enrollment":30,"indication":"Substance Withdrawal Syndrome","completionDate":"2008-05"},{"nctId":"NCT06729541","phase":"NA","title":"Development and Application of Precision Treatment Strategies for Patients with Depression, Bipolar Disorder, and Schizophrenia: a Multicenter Randomized Controlled Trial","status":"RECRUITING","sponsor":"Peking University","isPivotal":false,"enrollment":600,"indication":"Depression - Major Depressive Disorder, Schizophrenia Disorders","completionDate":"2026-12"},{"nctId":"NCT01960075","phase":"Phase 3","title":"A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory St","status":"COMPLETED","sponsor":"University of Virginia","isPivotal":true,"enrollment":478,"indication":"Benzodiazepine Refractory Status Epilepticus","completionDate":"2019-05"},{"nctId":"NCT01552434","phase":"Phase 1","title":"A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":155,"indication":"Advanced Malignant Neoplasm, Castleman Disease","completionDate":"2026-03-31"},{"nctId":"NCT06393309","phase":"N/A","title":"Investigation of Long-term Outcome of Levetiracetam and Valproate in Treatment of Idiopathic Generalized Epilepsy","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","isPivotal":false,"enrollment":169,"indication":"Treatment of Idiopathic Generalized Epilepsy","completionDate":"2024-03-19"},{"nctId":"NCT02213887","phase":"Phase 4","title":"A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","isPivotal":false,"enrollment":0,"indication":"Psychotic Disorders, Gastroesophageal Reflux","completionDate":"2020-11-02"},{"nctId":"NCT02473250","phase":"Phase 4","title":"Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":40,"indication":"Bipolar Disorder","completionDate":"2019-12"},{"nctId":"NCT05181007","phase":"Phase 1","title":"An Open-label, Two-stage Study Evaluating Drug-drug Interaction Between Ciprofol Injectable Emulsion and Mefanamic Acid or Valproate in Healthy Volunteers","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","isPivotal":false,"enrollment":41,"indication":"Drug Drug Interaction","completionDate":"2022-06-01"},{"nctId":"NCT00563992","phase":"Phase 1","title":"Pharmacotherapy of High-Risk Bipolar Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":98,"indication":"Bipolar Disorder","completionDate":"2008-10"},{"nctId":"NCT00358319","phase":"Phase 1","title":"Phase I/II Trial of Valproic Acid and Karenitecin for Metastatic Malignant Melanoma","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","isPivotal":false,"enrollment":42,"indication":"Malignant Melanoma","completionDate":"2007-04"},{"nctId":"NCT04486092","phase":"NA","title":"","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","isPivotal":false,"enrollment":200,"indication":"Bipolar Disorder","completionDate":"2021-07"},{"nctId":"NCT01170377","phase":"N/A","title":"The Effect of Valproate on the Required Dose of Propofol for Sedation in Patients With Mental Retardation","status":"COMPLETED","sponsor":"Okayama University","isPivotal":false,"enrollment":50,"indication":"Mental Retardation","completionDate":"2010-08"},{"nctId":"NCT01170325","phase":"Phase 2","title":"A Study of Divalproex Sodium in Children With Autism Spectrum Disorder and Epileptiform EEG","status":"WITHDRAWN","sponsor":"National Institute of Mental Health (NIMH)","isPivotal":false,"enrollment":0,"indication":"Autism, Autism Spectrum Disorders","completionDate":"2011-01-28"},{"nctId":"NCT00177567","phase":"Phase 4","title":"Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study","status":"COMPLETED","sponsor":"University of Pittsburgh","isPivotal":false,"enrollment":60,"indication":"Bipolar Disorder","completionDate":"2004-01"},{"nctId":"NCT00647712","phase":"Phase 1","title":"Single-Dose Fasting In Vivo Bioequivalence Study of Divalproex Sodium Extended-Release Tablets (500 mg; Mylan) to Depakote ER® Tablets (500 mg; Abbott) in Healthy, Adult Male Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":38,"indication":"Healthy","completionDate":"2004-12"},{"nctId":"NCT01333631","phase":"Phase 2","title":"Valproic Acid in Combination With Concurrent Chemoradiotherapy Using Gemcitabine for Unresectable Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Soroka University Medical Center","isPivotal":false,"enrollment":20,"indication":"Pancreatic Cancer","completionDate":"2015-07"},{"nctId":"NCT00524667","phase":"Phase 2","title":"HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"CancerCare Manitoba","isPivotal":false,"enrollment":6,"indication":"Chronic Lymphocytic Leukemia","completionDate":"2011-07"},{"nctId":"NCT02078596","phase":"Phase 4","title":"Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":15,"indication":"Irritable Aggression","completionDate":"2004-03"},{"nctId":"NCT01184391","phase":"Phase 1","title":"Single-Dose Fasting Bioequivalence Study of Divalproex Sodium Delayed-Release Tablets (500 mg; Mylan) and Depakote Tablets (500 mg; Abbott) in Healthy Adult Male And Female (Not of Childbearing Potent","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":17,"indication":"Healthy","completionDate":"2007-08"},{"nctId":"NCT02124174","phase":"Phase 2","title":"Maintenance Therapy With Azacitidine and Valproic Acid After Allogeneic Stem Cell Transplant in Patients With High-Risk Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)(Version 1_06 ","status":"UNKNOWN","sponsor":"Patrick Stiff","isPivotal":false,"enrollment":50,"indication":"Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS","completionDate":"2022-01"},{"nctId":"NCT01132183","phase":"Phase 1","title":"An Open Label, Balanced, Randomized, Two-treatment, Single-dose, Crossover, Bioequivalence Study of Divalproex Sodium Coated Particles in Capsules, 125 mg With Depakote® Sprinkle 125 mg in Healthy Hum","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":34,"indication":"Healthy","completionDate":"2007-03"},{"nctId":"NCT00175903","phase":"Phase 3","title":"A Therapeutic Confirmatory, Open-label, Multi-center, Randomized 2 Parallel Groups, Community-based Trial Studying the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral Tablets 250-500 mg","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":1701,"indication":"Epilepsy","completionDate":"2007-10"},{"nctId":"NCT00309686","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone as Adjunctive Therapy to Mood Stab","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":true,"enrollment":300,"indication":"Affective Psychosis, Bipolar, Bipolar Disorder","completionDate":"2007-08"},{"nctId":"NCT00004817","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","isPivotal":true,"enrollment":385,"indication":"Post-Traumatic Seizure Disorder, Head Injuries","completionDate":""},{"nctId":"NCT00075010","phase":"Phase 1","title":"Phase I/II Study of 5-aza-2'-Deoxycytidine and Valproic Acid in Patients With Relapsed/Refractory Leukemia or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":54,"indication":"Leukemia, Myelodysplastic Syndromes","completionDate":"2006-11-08"},{"nctId":"NCT00356018","phase":"N/A","title":"Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy: A Randomized, Parallel, Prospectively-Controlled ","status":"COMPLETED","sponsor":"Orlando Health, Inc.","isPivotal":false,"enrollment":5,"indication":"Epilepsy","completionDate":"2007-05"},{"nctId":"NCT00195780","phase":"Phase 3","title":"An Open-Label Study to Evaluate the Safety of Depakote ER in the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents","status":"COMPLETED","sponsor":"Abbott","isPivotal":true,"enrollment":227,"indication":"Bipolar I Disorder","completionDate":""},{"nctId":"NCT00579280","phase":"Phase 4","title":"A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Gene","status":"COMPLETED","sponsor":"University of South Florida","isPivotal":false,"enrollment":224,"indication":"Bipolar Disorder, Panic Disorder","completionDate":"2010-12"},{"nctId":"NCT00223496","phase":"Phase 4","title":"12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","isPivotal":false,"enrollment":32,"indication":"Bipolar Disorder","completionDate":"2009-09"},{"nctId":"NCT07166393","phase":"Phase 2","title":"Multi-institutional Phase 2/3 Trial of Valproic Acid in Patients With Moderate to Severe Traumatic Brain Injury","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","isPivotal":true,"enrollment":432,"indication":"Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury","completionDate":"2030-12"},{"nctId":"NCT02446652","phase":"Phase 3","title":"Phase III Clinical Trial: \"Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer","status":"WITHDRAWN","sponsor":"National Institute of Cancerología","isPivotal":true,"enrollment":0,"indication":"Cervical Cancer","completionDate":"2018-08"},{"nctId":"NCT00308360","phase":"Phase 4","title":"Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility","status":"COMPLETED","sponsor":"Nathan Kline Institute for Psychiatric Research","isPivotal":false,"enrollment":46,"indication":"Schizophrenia","completionDate":"2004-04"},{"nctId":"NCT02872428","phase":"Phase 1","title":"A Phase 1, Single Ascending Dose, Double Blind, Placebo Controlled Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1) or Trauma Patients(Part 2)","status":"TERMINATED","sponsor":"Dr. Hasan Alam","isPivotal":false,"enrollment":1,"indication":"Shock,Hemorrhagic, Trauma","completionDate":"2017-09-29"},{"nctId":"NCT01861990","phase":"Phase 1","title":"Valproic Acid for Children With Recurrent and Progressive Brain Tumors","status":"WITHDRAWN","sponsor":"Medical University of South Carolina","isPivotal":false,"enrollment":0,"indication":"Pediatric Brain Tumor, Glioma","completionDate":"2013-12"},{"nctId":"NCT00414310","phase":"Phase 2","title":"Phase II Randomized Study of Low-Dose Decitabine (5-AZA-2'-Deoxycytidine) With or Without Valproic Acid in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia -\"SPORE\"","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":153,"indication":"Myelodysplastic Syndrome, Acute Myelogenous Leukemia","completionDate":"2015-05"},{"nctId":"NCT05263674","phase":"Phase 3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","isPivotal":true,"enrollment":140,"indication":"Non-Convulsive Status Epilepticus","completionDate":"2028-12-31"},{"nctId":"NCT06714357","phase":"Phase 2","title":"Randomized Phase 2 Study of Valproic Acid Combined With Rechallenge Anti-EGFR Based Regimen Regimens in Pretreated Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer - VICTORIA Trial","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","isPivotal":false,"enrollment":130,"indication":"Colorectal Cancer Metastatic","completionDate":"2027-06-20"},{"nctId":"NCT00879437","phase":"Phase 2","title":"A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas","status":"COMPLETED","sponsor":"Baylor College of Medicine","isPivotal":false,"enrollment":38,"indication":"Glial Cell Tumors, Malignant Gliomas","completionDate":"2017-10-02"},{"nctId":"NCT03357757","phase":"Phase 2","title":"The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus","status":"COMPLETED","sponsor":"AHS Cancer Control Alberta","isPivotal":false,"enrollment":39,"indication":"Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN","completionDate":"2025-03-31"},{"nctId":"NCT02896270","phase":"Phase 2","title":"A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","isPivotal":true,"enrollment":15,"indication":"Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis","completionDate":"2019-12"},{"nctId":"NCT02300051","phase":"NA","title":"Sexual Risk Behavior, Clinical and Psychopathological Aspects of Individuals With Compulsive Sexual Behavior of the Institute of Psychiatry of the General Hospital of the University of São Paulo Medic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","isPivotal":false,"enrollment":135,"indication":"Compulsive Sexual Behavior","completionDate":"2015-07"},{"nctId":"NCT00374075","phase":"Phase 1","title":"In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy","status":"COMPLETED","sponsor":"University of Utah","isPivotal":false,"enrollment":42,"indication":"Spinal Muscular Atrophy","completionDate":"2006-02"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=sodium valproate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:30:35.806259+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:30:42.644804+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sodium valproate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:30:43.204349+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Succinate semialdehyde dehydrogenase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:30:44.748111+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL433/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:30:44.406017+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:30:46.078373+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL433"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}